NICE Gives Thumbs Up to Sanofi’s Prostate Cancer Candidate

In a change of heart from earlier draft guidance, the UK’s National Institute for Health and Care Excellence has recommended reimbursement for Sanofi’s Jevtana for treating prostate cancer.

The cost watchdog previously spurned the drug over concerns about its cost-effectiveness versus standard treatments.

Sanofi, however, increased the discount and agreed to supply the treatment in IV bags instead of vials to reduce waste. Its list price is roughly $5,300 per 60-mg vial.